YOYasuyuki Ohta

Yasuyuki Ohta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yasuyuki Ohta has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Koji Abe

    Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata‐cho, Okayama, Japan

    2 shared publications
  • Makiko Nagai

    Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata‐cho, Okayama, Japan

    2 shared publications
  • Tetsuro Murakami

    Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata‐cho, Okayama, Japan

    2 shared publications
  • Tetsuya Nagata

    Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata‐cho, Okayama, Japan

    2 shared publications
  • Tomoko Kurata

    Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata‐cho, Okayama, Japan

    2 shared publications
  • Hisashi Narai

    Department of Neurology, Graduate School of Medicine, Dentistry and Pharmacy, Okayama University, Okayama, Japan

    1 shared publication

Latest Publications

  • Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis

    by Yasuyuki Ohta, Tatsushi Kamiya, Makiko Nagai, Tetsuya Nagata, Nobutoshi Morimoto, Kazunori Miyazaki, Tetsuro Murakami, Tomoko Kurata, Yasushi Takehisa, Yoshio Ikeda, et al.

    When fused with the protein transduction domain (PTD) derived from the human immunodeficiency virus TAT protein, proteins can cross the blood–brain barrier and cell membrane and transfer into several tissues, including the brain, making protein therapy feasible for various neurological disorders. We have constructed a powerful antiapoptotic modified Bcl‐XLprotein (originally constructed from Bcl‐XL) fused with PTD derived from TAT (TAT‐modified Bcl‐XL), and, to examine its clinical effectiveness in a mouse model of familial amyotrophic lateral sclerosis (ALS), transgenic mice expressing human Cu/Zn superoxide dismutase (SOD1) bearing a G93A mutation were treated by intrathecal infusion of TAT‐modified Bcl‐XL. We demonstrate that intrathecally infused TAT‐fused protein was effectively transferred into spinal cord neurons, including motor neurons, and that intrathecal infusion of TAT‐modified Bcl‐XLdelayed disease onset, prolonged survival, and improved motor performance. Histological studies show an attenuation of motor neuron loss and a decrease in the number of cleaved caspase 9‐, cleaved caspase 3‐, and terminal deoxynucleotidyl transferase‐mediated dUTP nick‐end labeling (TUNEL)‐positive cells in the lumbar cords of TAT‐modified Bcl‐XL‐treated G93A mice. Our results indicate that intrathecal protein therapy using a TAT‐fused protein is an effective clinical tool for the treatment of ALS.


  • Intrathecal injection of epidermal growth factor and fibroblast growth factor 2 promotes proliferation of neural precursor cells in the spinal cords of mice with mutant human SOD1 gene

    by Yasuyuki Ohta, Makiko Nagai, Tetsuya Nagata, Tetsuro Murakami, Isao Nagano, Hisashi Narai, Tomoko Kurata, Mito Shiote, Mikio Shoji, Koji Abe

    We investigated three steps of neural precursor cell activation—proliferation, migration, and differentiation—in amyotrophic lateral sclerosis spinal cord treated with intrathecal infusion of epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF2) into the lumbar spinal cord region of normal and symptomatic transgenic (Tg) mice with a mutant human Cu/Zn superoxide dismutase (SOD1) gene. We observed that 5‐bromodeoxyuridine (BrdU) + nestin double‐labeled neural precursor cells increased in the spinal cords of Tg mice compared with non‐Tg mice, with a much greater increase produced by EGF and FGF2 treatment. The number of BrdU + nestin double‐labeled cells was larger than that of BrdU + ionized calcium‐binding adapter molecule‐1 (Iba1), BrdU + glial fibrillary acidic protein (GFAP), or BrdU + highly polysialylated neural cell adhesion molecule (PSA‐NCAM) double‐labeled cells, but none expressed neuronal nuclear antigen (NeuN). On further analysis of the gray matter of Tg mice, the number of BrdU + nestin and BrdU + PSA‐NCAM double‐labeled cells increased more in the ventral horns than the dorsal horns, which was again greatly enhanced by EGF and FGF2 treatment. Because neural precursor cells reside close to the ependyma of central canal, the present study suggests that proliferation and migration of neural precursor cells to the ventral horns is greatly activated in symptomatic Tg mice and is further enhanced by EGF and FGF2 treatment and, furthermore, that the neural precursor cells preferentially differentiate into neuronal precursor cells instead of astrocytes in Tg mice with EGF and FGF2 treatment.